Congestive Heart Failure
Supplements studied for congestive heart failure.
Overview
Congestive heart failure has the strongest supplement signal for Coenzyme Q10 (31 studies). Added to usual therapy, coenzyme Q10 may reduce mortality and hospitalization and slightly improve exercise tolerance and breathlessness in available research.
L-Carnitine and Hawthorn show mixed symptomatic benefits in smaller heart failure trials without consistent effects on hard outcomes. Selenium combined with coenzyme Q10 over several years reduced cardiac deaths in older adults with low baseline selenium. Panax Ginseng improved assessed heart function in one small short trial without a control group. See the heatmap and evidence reviews below.
Effect graph
Relevant supplements
Relevant supplements sorted by DEX Score.
| L-Carnitine | ★★★★★ | Medium |
| Coenzyme Q10 | ★★★★★ | Medium |
| Hawthorn | ★★★★★ | Low |
| Selenium | ★★★★★ | Low |
| Panax Ginseng | ★★★★★ | Low |
Studies
Find individual evidence reviews for supplements sorted by DEX Score.
5 supplements for and rated at least stars. All purchase bands. No minimum star filter.
Coenzyme Q10View supplement →
Consider purchase·★★★★★
How we scored this▸
- Taking coenzyme Q10 by mouth may help people with congestive heart failure when used with their usual medicines.
- Research suggests that coenzyme Q10 can lower the risk of death and hospital stays, and slightly improve the ability to exercise.
- It may also help lessen symptoms like shortness of breath, swelling, and trouble sleeping in people with more severe heart failure.
- Some studies show it reduces the risk of atrial fibrillation.
- Not all studies agree and coenzyme Q10 does not always improve heart function or how severe the condition is.
- Benefits may depend on the amount taken, how long it’s used, how severe the heart failure is, and which other medicines are used at the same time.
Browse 31 studies·6 meta-analyses
MetaEfficacy and safety of coenzyme Q10 in heart failure: a meta-analysis of randomized controlled trials2024
A meta-analysis of 33 heart failure RCTs found CoQ10 lowered all-cause mortality (RR 0.64), HF hospitalization (RR 0.50), NYHA class, BNP, and improved LVEF and 6-minute walk distance.
- Effect
- Benefit
- Dose
- 10 g/day
MetaEvaluating the efficacy of ubiquinol in heart failure patients: a systematic review and meta-analysis2024
A meta-analysis of 16 heart failure studies found CoQ10 reduced HF-related mortality by 40% and improved exercise capacity, with no significant LVEF difference.
- Effect
- Benefit
- Population
- Heart failure patients
RCTEffects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction2022n=216
In 216 HFpEF patients aged 50+, 12 weeks of ubiquinol (600 mg/day) and/or d-ribose (15 g/day) improved symptom scores, ejection fraction, and BNP versus placebo.
- Effect
- Benefit
- Duration
- 12 weeks
- Dose
- 600 mg/day
- Population
- HFpEF patients
- Participants
- 216
- Ages
- 50+
MetaCoenzyme Q10 for heart failure2021n=1,573
A Cochrane review of 11 heart failure trials (1573 participants) found CoQ10 probably reduced all-cause mortality (RR 0.58) and HF hospitalization (RR 0.62) versus control.
- Effect
- Benefit
- Participants
- 1,573
MetaEfficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials2017n=2,149
A meta-analysis of 14 RCTs in 2149 heart failure patients found CoQ10 reduced mortality (RR 0.69) and improved exercise capacity, with no significant LVEF or NYHA differences.
- Effect
- Benefit
- Population
- Heart failure patients
- Participants
- 2,149
RCTEffect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure2015n=12
In 102 heart failure patients followed 6–12 months, adjunct CoQ10 reduced atrial fibrillation incidence to 6.3% versus 22.2% in controls (P=0.02) and lowered malondialdehyde.
- Effect
- Benefit
- Dose
- 2 g/day
- Population
- Heart failure patients
- Participants
- 12
- Ages
- 45–82
RCTThe effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial2014n=420
In 420 moderate-to-severe chronic HF patients, 300 mg/day CoQ10 for 2 years reduced major adverse cardiovascular events to 15% versus 26% with placebo (HR 0.50; P=0.003).
- Effect
- Benefit
- Duration
- 2 years
- Dose
- 300 mg/day
- Population
- Heart failure patients
- Participants
- 420
MetaEffect of coenzyme Q₁₀ supplementation on heart failure: a meta-analysis2013
A meta-analysis of CoQ10 RCTs in heart failure found a pooled 3.67% ejection fraction gain, with greater benefit in less severe HF and doses ≤100 mg/day.
- Effect
- Benefit
- Dose
- 100 mg/day
- Population
- Heart failure patients
RCTCoenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study2011n=35
In 67 stable systolic HF patients, 8 weeks of water-soluble CoQ10 (320 mg/day) plus creatine (340 mg/day) raised peak VO2 by 1.8 mL/min/kg more than placebo.
- Effect
- Benefit
- Duration
- 8 weeks
- Dose
- 320 mg/day
- Population
- Heart failure patients
- Participants
- 35
Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM)2008n=46
In 46 hypertrophic cardiomyopathy patients, adding 200 mg/day CoQ10 to usual care improved diastolic function and reduced interventricular septal thickness by 22.4% versus conventional therapy alone.
- Effect
- Benefit
- Dose
- 200 mg/day
- Population
- Heart failure patients
- Participants
- 46
ObservationalCoenzyme Q10: an independent predictor of mortality in chronic heart failure2008n=236
In 236 hospitalized heart failure patients followed a median 2.7 years, low plasma CoQ10 independently predicted higher mortality (HR 2.0 at ROC cut-point).
- Effect
- No Benefit
- Population
- Heart failure patients
- Participants
- 236
- Ages
- 50+
RCTCoenzyme Q10 and exercise training in chronic heart failure2006n=23
A study of 23 patients (In NYHA class II or III) found that 100 mg/day coenzyme Q10 supplementation improves endothelial function, functional capacity and left ventricular contractility. A combination of exercise (5x per week at 60% VO2 Max) and supplementation led to a greater increase in plasma coenzyme Q10 levels and larger benefits in all abovementioned markers of heart function.
- Effect
- Benefit
- Duration
- 4 weeks
- Dose
- 100 mg/day
- Population
- Heart failure patients
- Participants
- 23
- Avg age
- ~59
MetaThe impact of coenzyme Q10 on systolic function in patients with chronic heart failure2006n=277
A meta-analysis of 10 heart failure trials (277 patients) found CoQ10 at 60–200 mg/day for 1–6 months improved ejection fraction by 3.7% (95% CI 1.59–5.77).
- Effect
- Benefit
- Duration
- 1–6 months
- Dose
- 200 mg/day
- Population
- Heart failure patients
- Participants
- 277
RCTCoenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure2005n=21
In 21 NYHA class II–III HF patients, 100 mg CoQ10 three times daily for 4 weeks improved left ventricular contractility and peak VO2 by 13% versus placebo in a crossover trial.
- Effect
- Benefit
- Duration
- 4 weeks
- Dose
- 100 mg 3×/day
- Population
- Heart failure patients
- Participants
- 21
- Avg age
- ~59
RCTCoenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study2004n=27
In 27 end-stage heart failure patients awaiting transplant, 60 mg/day CoQ10 for 3 months improved 6-minute walk distance and symptoms but did not change echocardiography or ANF/TNF levels.
- Effect
- Benefit
- Duration
- 3 months
- Dose
- 60 mg/day
- Population
- Heart failure patients
- Participants
- 27
RCTRandomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure2003n=18
In 35 NYHA class II–III HF patients on ACE inhibitors, 150 mg/day CoQ10 for 3 months improved NYHA class by 0.5 and 6-minute walk distance versus placebo.
- Effect
- Benefit
- Duration
- 3 months
- Dose
- 150 mg/day
- Population
- Heart failure patients
- Participants
- 18
Systematic reviewSystematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure2003n=300
A systematic review found 6 of 11 exercise trials showed modest CoQ10 benefit, 8 hypertension trials averaged 16/10 mmHg BP reductions, and a 35-patient HF pilot showed symptom gains with inconclusive mortality trends in 9 HF trials.
- Effect
- Benefit
- Duration
- 3 months
- Population
- Heart failure patients
- Participants
- 300
RCTThe effect of coenzyme Q10 in patients with congestive heart failure2000n=46
In 46 NYHA class III–IV HF patients, 200 mg/day CoQ10 for an unspecified duration raised serum CoQ10 but did not change ejection fraction, peak oxygen consumption, or exercise duration versus placebo.
- Effect
- No Benefit
- Dose
- 200 mg/day
- Population
- Heart failure patients
- Participants
- 46
Controlled trialCoenzyme Q10 treatment in serious heart failure1999n=22
In 22 severe HF patients, 100 mg CoQ10 twice daily for 12 weeks improved stroke index and reduced pulmonary pressures at rest and during exercise versus placebo.
- Effect
- Benefit
- Duration
- 12 weeks
- Dose
- 100 mg 2×/day
- Population
- Heart failure patients
- Participants
- 22
RCTLack of effect of coenzyme Q10 on left ventricular function in patients with congestive heart failure1999n=30
In 27 dilated cardiomyopathy patients, 3 months of oral CoQ10 did not improve ejection fraction, cardiac volumes, hemodynamics, or quality of life despite doubling plasma CoQ levels.
- Effect
- No Benefit
- Duration
- 3 months
- Population
- Heart failure patients
- Participants
- 30
MetaTreatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials1997
A meta-analysis of 8 HF RCTs (1984–1994) found CoQ10 improved stroke volume, ejection fraction, cardiac output, and cardiac index versus placebo.
- Effect
- Benefit
- Population
- Heart failure patients
Controlled trialEffect of protection and repair of injury of mitochondrial membrane-phospholipid on prognosis in patients with dilated cardiomyopathy1996
In 61 hospitalized dilated cardiomyopathy patients, 12 weeks of CoQ10 or captopril improved heart function and raised 2-year survival to 72.7% and 64.0% versus 24.7% with placebo.
- Effect
- Benefit
- Duration
- 12 weeks
- Population
- Heart failure patients
RCTCoenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group1995n=79
In 79 chronic HF patients (mean age 61), 100 mg/day CoQ10 for 3 months slightly increased exercise capacity (94 to 100 W; P<0.05) and quality-of-life scores versus placebo.
- Effect
- Benefit
- Duration
- 3 months
- Dose
- 100 mg/day
- Population
- Heart failure patients
- Participants
- 79
- Avg age
- 61±10
Clinical trialItalian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators1994n=2,664
An open 3-month Italian surveillance study in 2664 NYHA II–III HF patients on 50–150 mg/day CoQ10 reported symptom improvement in most patients with a 1.5% adverse event rate.
- Effect
- Benefit
- Duration
- 3 months
- Dose
- 100 mg/day
- Population
- Heart failure patients
- Participants
- 2,664
RCTNoninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment1994
In 6 chronic HF patients, 4 weeks of CoQ10 raised resting and peak-exercise ejection fraction versus placebo in a crossover VEST hemodynamic study.
- Effect
- Benefit
- Duration
- 4 weeks
- Population
- Heart failure patients
RCTEffect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study1993n=73
In 641 chronic HF patients, 1 year of CoQ10 at 2 mg/kg/day reduced hospitalizations for worsening HF (73 vs 118) and episodes of pulmonary edema versus placebo.
- Effect
- Benefit
- Dose
- 2 mg/kg
- Population
- Heart failure patients
- Participants
- 73
- Ages
- 30–88
Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure1993
An open multicenter study in 1715 outpatients with chronic HF found 50 mg/day CoQ10 for 4 weeks improved dyspnea, edema, heart rate, and blood pressure on standard therapy.
- Effect
- Benefit
- Duration
- 3 months
- Dose
- 50 mg/day
- Population
- Heart failure patients
RCTRole of metabolic therapy in cardiovascular disease1993
In heart failure patients treated with 100 mg/day ubiquinone for 7 months, echocardiographic systolic function, cardiothoracic ratio, and clinical symptoms improved versus baseline.
- Effect
- Benefit
- Duration
- 7 months
- Dose
- 100 mg/day
- Population
- Heart failure patients
RCTUbiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy1992n=25
In 25 idiopathic dilated cardiomyopathy patients, 100 mg/day ubiquinone for 4 months in a crossover design did not improve echocardiographic function, arrhythmias, or exercise tolerance.
- Effect
- No Benefit
- Duration
- 4 months
- Dose
- 100 mg/day
- Population
- Patients with dilated cardiomyopathy
- Participants
- 25
Controlled trialUsefulness of taurine in chronic congestive heart failure and its prospective application1992n=17
In 17 HF patients, 6 weeks of 3 g/day taurine improved systolic left ventricular function on echocardiography, while 30 mg/day CoQ10 did not.
- Effect
- No Benefit
- Duration
- 6 weeks
- Dose
- 3 g/day
- Population
- Heart failure patients
- Participants
- 17
Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure1990n=45
In 40 severe HF patients (NYHA III–IV), 100 mg/day CoQ10 in an open study improved symptoms in 69% with cardiomyopathy and 43% with ischemic disease, with no adverse reactions reported.
- Effect
- Benefit
- Dose
- 100 mg/day
- Population
- Heart failure patients
- Participants
- 45
L-CarnitineView supplement →
Consider purchase·★★★★★
How we scored this▸
- In people with chronic heart failure, some small studies suggest that L-carnitine may help improve symptoms and exercise ability.
- Doses studied have included 1.5–3 g per day by mouth for up to almost 3 years, or 5 g per day by IV for 1 week.
- A supplement combining L-carnitine (2250 mg) with coenzyme Q10 (270 mg) taken daily for 12 weeks has also shown improvement in symptoms compared with no treatment.
Browse 6 studies
Controlled trial[Clinical efficacy of intravenous L-carnitine in patients with right-sided heart failure induced by pulmonary arterial hypertension]2010n=38
In 38 PAH patients with right heart failure, IV L-carnitine 5 g/day improved functional class and exercise capacity versus baseline.
- Effect
- Benefit
- Duration
- 7 days
- Dose
- 5 g/day
- Population
- Heart failure patients
- Participants
- 38
RCTL-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms2010n=29
In 29 mild diastolic heart failure patients, L-carnitine 1,500 mg/day for 3 months improved diastolic function indices versus baseline.
- Effect
- Benefit
- Duration
- 3 months
- Dose
- 1500 mg/day
- Population
- Heart failure patients
- Participants
- 29
RCTEffect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study2007n=31
In 31 heart failure patients, carni Q-gel (ubiquinol plus carnitine) 2,250 mg/day for 12 weeks reduced pro-inflammatory cytokines versus baseline.
- Effect
- Benefit
- Duration
- 12 weeks
- Dose
- 2250 mg/day
- Population
- Heart failure patients
- Participants
- 31
RCTThree-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration2000n=80
In 80 dilated cardiomyopathy patients, L-carnitine for up to 3 years improved survival versus historical control with reduced cardiac events.
- Effect
- Benefit
- Duration
- 10–54 months
- Dose
- 2 g/day
- Population
- Adults
- Participants
- 80
RCTProlonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency1999n=41
In 41 healthy adults, oral L-carnitine 3 g/day for 120 days increased peak VO2 and power output on bicycle ergometry versus baseline.
- Effect
- Benefit
- Duration
- 120 days
- Dose
- 3 g/day
- Population
- Heart failure patients
- Participants
- 41
RCTEvaluation of the therapeutic efficacy of L-carnitine in congestive heart failure1988n=38
In 38 elderly heart failure patients, L-carnitine for 45 days improved exercise tolerance and cardiac function indices versus baseline.
- Effect
- Benefit
- Duration
- 45 days
- Population
- Older adults
- Participants
- 38
- Ages
- 65–82
HawthornView supplement →
Reconsider purchase·★★★★★
How we scored this▸
- Studies on hawthorn extract for heart failure show mixed results.
- Some smaller studies suggest it may improve symptoms and exercise capacity in people with mild to moderate heart failure, but larger and more recent research did not show clear benefits for hospital stays, complications, or death.
- More research is needed before it can be considered reliable.
Browse 12 studies·1 meta-analysis
RCT[Hawthorn extract WS 1442 in the treatment of patients with heart failure and LVEF of 25%-35%]2010
In heart failure patients with LVEF 25–35%, hawthorn extract WS 1442 improved symptoms and cardiac function versus control in a clinical trial.
- Effect
- Benefit
- Population
- Heart failure patients
RCTHawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial2009
In 120 ambulatory NYHA II–III heart failure patients over 6 months, hawthorn extract (450 mg twice daily) as add-on therapy did not improve exercise capacity versus placebo.
- Effect
- No Benefit
- Duration
- 6 months
- Dose
- 450 mg 2×/day
- Population
- Heart failure patients
- Ages
- ≥18
MetaHawthorn extract for treating chronic heart failure2008n=380
A Cochrane meta-analysis of hawthorn for chronic heart failure (380 participants across trials) found small improvements in symptoms and exercise capacity versus placebo.
- Effect
- Benefit
- Population
- Heart failure patients
- Participants
- 380
RCTThe effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure2008
In HERB CHF trial patients with mild-to-moderate heart failure, WS 1442 (900 mg/day) for 6 months slowed clinical deterioration versus placebo (46.6% vs higher progression on placebo).
- Effect
- No Benefit
- Duration
- 6 months
- Dose
- 900 mg/day
- Population
- Heart failure patients
RCTThe efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial2008n=2,681
In the SPICE trial (2,681 NYHA II–III heart failure patients over 24 months), WS 1442 (900 mg/day) did not reduce cardiovascular mortality or hospitalization versus placebo.
- Effect
- No Benefit
- Duration
- 24 months
- Dose
- 900 mg/day
- Population
- Adults
- Participants
- 2,681
RCTA randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II2003n=74
In 143 NYHA II heart failure patients over 8 weeks, Crataegisan (fresh hawthorn berry extract) modestly improved exercise tolerance and symptoms versus placebo.
- Effect
- Benefit
- Duration
- 8 weeks
- Population
- Heart failure patients
- Participants
- 74
- Avg age
- ~65
RCTEfficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure2002n=209
In 209 NYHA III heart failure patients over 16 weeks, crataegus WS 1442 (1,800 mg/day) improved exercise tolerance and symptoms versus placebo.
- Effect
- Benefit
- Duration
- 16 weeks
- Dose
- 800 mg/day
- Population
- Heart failure patients
- Participants
- 209
RCTClinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II2001
In 40 NYHA II heart failure patients over 12 weeks, WS 1442 improved exercise tolerance and heart failure symptoms versus placebo.
- Effect
- Benefit
- Duration
- 12 weeks
- Population
- Heart failure patients
RCT[Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]1996n=136
In 136 NYHA II heart failure patients over 8 weeks, WS 1442 improved exercise performance and cardiac function measures versus placebo.
- Effect
- Benefit
- Duration
- 8 weeks
- Population
- Heart failure patients
- Participants
- 136
RCTEfficacy of the Hawthorn (Crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II1994n=78
In 78 NYHA II heart failure patients over 8 weeks, hawthorn extract LI 132 (600 mg/day) improved exercise performance and symptoms versus placebo.
- Effect
- Benefit
- Duration
- 8 weeks
- Dose
- 600 mg/day
- Population
- Adults
- Participants
- 78
- Ages
- 45–73
RCT[Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study]1993n=30
In 30 NYHA II heart failure patients over 8 weeks, WS 1442 (twice daily) improved cardiac performance and symptom scores versus placebo.
- Effect
- Benefit
- Duration
- 8 weeks
- Population
- Heart failure patients
- Participants
- 30
Clinical trial[The clinical effect of Crataegutt in heart disease of ischemic or hypertensive origin. A multicenter double-blind study]1981
In a multicenter double-blind trial, Crataegutt improved symptoms in patients with ischemic or hypertensive heart disease versus placebo.
- Effect
- Benefit
SeleniumView supplement →
Reconsider purchase·★★★★★
How we scored this▸
- Taking selenium together with coenzyme Q10 for several years helped older adults with heart failure live longer by reducing deaths from heart problems.
- This effect was strongest in people who had low selenium levels to start with.
- It’s not known if selenium alone or the combination with coenzyme Q10 provided the benefit.
Browse 4 studies
RCTStill reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly2018n=228
Twelve-year follow-up of 443 elderly Swedes found 4 years of selenium plus coenzyme Q10 continued to associate with lower cardiovascular mortality (28.1% vs 38.7%).
- Effect
- Benefit
- Dose
- 200 mg/day
- Population
- Older adults
- Participants
- 228
RCTSupplementation with Selenium and Coenzyme Q10 Reduces Cardiovascular Mortality in Elderly with Low Selenium Status. A Secondary Analysis of a Randomised Clinical Trial2016n=449
Secondary analysis of 668 elderly Swedes found selenium plus coenzyme Q10 for 4 years reduced cardiovascular mortality most in those with low baseline selenium.
- Effect
- Benefit
- Duration
- 4 years
- Dose
- 200 mg
- Population
- Older adults
- Participants
- 449
- Ages
- 70–80
RCTReduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens2015n=70
Ten-year follow-up of 443 elderly Swedes confirmed 4 years of selenium plus coenzyme Q10 reduced cardiovascular mortality (HR 0.51) versus placebo.
- Effect
- Benefit
- Duration
- 10 years
- Dose
- 200 mg/day
- Population
- Adults
- Participants
- 70
RCTCardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens2013n=443
In 443 elderly Swedes over 5 years, combined selenium and coenzyme Q10 for 4 years significantly reduced cardiovascular mortality versus placebo.
- Effect
- Benefit
- Duration
- 4 years
- Population
- Older adults
- Participants
- 443
- Ages
- 70–88
Panax GinsengView supplement →
Reconsider purchase·★★★★★
How we scored this▸
- It is uncertain if Panax ginseng helps people with congestive heart failure.
- In a small study, taking 2 grams of Panax ginseng daily for 15 days improved heart function based on doctor assessments.
- It may also improve blood flow and work well with the medication digoxin, but the study did not include a comparison group, so results are not conclusive.
Browse 1 study
RCT[Effects of red ginseng on the congestive heart failure and its mechanism]1995n=45
In 45 class IV heart failure patients, red ginseng plus digoxin showed greater hemodynamic and biochemical improvement than digoxin alone, with red ginseng also effective as monotherapy.
- Effect
- Benefit
- Population
- Patients with heart failure
- Participants
- 45
Evidence visualised
Same ratings as above, aggregated so you can see coverage and imbalance.
| Supplement | DEX | Studies | Meta-analyses | Share |
|---|---|---|---|---|
| Coenzyme Q10 | ★★★★★68% | 31 | 6 | 57% |
| Hawthorn | ★★★★★56% | 12 | 1 | 22% |
| L-Carnitine | ★★★★★68% | 6 | 0 | 11% |
| Selenium | ★★★★★48% | 4 | 0 | 7% |
| Panax Ginseng | ★★★★★44% | 1 | 0 | 2% |